Comments on: Effects of clarithromycin in patients with active rheumatoid arthritis [3]

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2763-2764

  Saviola, Gianantonio ^a   Benucci, Maurizio ^b   Cirino, Giuseppe ^c  

^a IRCCS   (Italy)

^b New Hospital San Giovanni di Dio   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PHOSPHOLIPASE A2; PROSTAGLANDIN E2; STEROID; SYROLIMUS; TACROLIMUS; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; CLINICAL STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; LETTER; MEDICAL DECISION MAKING; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ARTHRITIS, RHEUMATOID; CLARITHROMYCIN; FEMALE; HUMANS; MALE; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 36349025840     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242511     Document Type: Letter

References (16)

1. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:1-8
2. Ishida Y, Abe Y, Harabuchi Y. Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes. Int J Pediatr Otorhinolaringol 2007;71(2):297-305
3. Terao H, Asano K, Kanal K, et al. Suppressive activity of macrolides antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators Inflamm 2003;12: 195-202
4. Miyazaky M, Zaitsu M, Honjo K, et al. Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes. Prostaglandins Leukot Essent Fatty Acids 2003;69:229-35
5. Inoue S, Nakase H, Matsuura M, et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. J Gastroenterol Hepatol 2007;22(7):984-8
6. Saviola G, Abdi-Ali L, Cirino G, et al. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: an open, uncontrolled pilot study. Clin Exp Rheumatol 2002;20:373-8
7. Saviola G, Abdi-Ali L, Shams-Eddin S, et al. Clarithromycin in adult-onset Still's disease. Case report with 1-year follow-up. Clin Exp Rheumatol, 2004;22:379
8. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin 2007;23(3):515-22
9. Rashid T, Darlington G, Kjeldsen-Kregh J, et al: Proteus IgG antibodies and C-reactive protein in English, Norwegian and Spanish patients with rheumatoid arthritis. Clin Rheumatol 1999;18(3):190-5
10. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Net Rev Immunol 2007;7(2):161-7
11. Hernandez-Cruz B, Cardiel MH, Villa AR, et al. Developement, recurrence and severity of infections in Mexicans patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998;25(10):1900-7
12. Symmons DP. Mortality in rheumatoid arthritis. Br J Rheumatol 1998;27(Suppl 1):44-54
13. Firestein GS, Panayi GS, Wollheim FA. Rheumatoid Arthritis. New Frontiers in Pathogenesis and Treatment, Oxford University Press, Oxford, UK, 2000
14. van der Veen MJ, van der Heide A, Kruize AA, et al. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53(4):224
15. Doran MF, Crowson CS, Pond GR, et al: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46(9):2287-93
16. Moskowitz RW, Lesko M, Hooper M. Open-label study of clarithromycin in patients with undifferentiated connective tissue disease. Semin Arthritis Rheum 2006;36:82-7